Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean dlhapi mm (1 results)?
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial.
Borges ÁH, Russell M, Tait D, Scriba TJ, Nemes E, Skallerup P, van Brakel E, Cabibbe AM, Cirillo DM, Leuvennink-Steyn M, Rutkowski KT, Wood GK, Thierry-Carstensen B, Tingskov PN, Meldgaard EC, Kristiansen MP, Søndergaard RE, Hansen CH, Follmann F, Jensen CG, Gela A, Ntinginya NE, Ruhwald M, Shenje J, White L, Innes C, Selepe P, Ngaraguza B, Holmgren C, Collings T, Andersen P, Dawson R, Churchyard G, Sabi I, Diacon AH, Mortensen R, Hatherill M; POR TB study group. Borges ÁH, et al. Lancet Infect Dis. 2025 Jul;25(7):751-763. doi: 10.1016/S1473-3099(24)00814-4. Epub 2025 Mar 5. Lancet Infect Dis. 2025. PMID: 40056922 Clinical Trial.
Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trial.
Govender V, Reddy T, Maenetje P, Beattie T, Adonis T, Nielson T, Moodley J, Mdluli J, Bhoola A, Angelo S, Panchia R, Mngadi K, Innes C, Brumskine W, Mlotshwa M, Nhlangulela L, Ncube I, Moyo-Gwete T, Moore PL, Keeton RS, Burgers W, Kumar K, Garg N, Tripathi A, Sayed S, Matsimela K, Mchunu N, Wallis R, Edward VA, Churchyard GJ; COVID-19 Vaccine Strategies study group. Govender V, et al. Lancet HIV. 2026 Mar;13(3):e163-e175. doi: 10.1016/S2352-3018(25)00275-9. Epub 2026 Feb 11. Lancet HIV. 2026. PMID: 41690324 Clinical Trial.